Hori Hikaru
   Department   School of Medicine  Psychiatry, Clinical Medical Sciences
Article types journal article
Language English
Peer review Peer reviewed
Title The Nursing Assessment of Medication Acceptance: the reliability and validity of a schizophrenia medication adherence scale.
Journal Formal name:Therapeutic advances in psychopharmacology
Abbreviation:Ther Adv Psychopharmacol
ISSN code:20451253/20451253
Domestic / ForeginForegin
Volume, Issue, Page 7(1),11-16頁
Author and coauthor Hori Hikaru, Ueda Nobuhisa, Shiozuka Hideki, Igata Ryohei, Miki Tazuko, Atake Kiyokazu, Takeuchi Yuji, Shirozu Hiroaki, Ohara Naotoshi, Konishi Yuki, Nagai Hiroshi, Sakurai Noriaki, Kubota Takanori, Yoshimura Reiji
Publication date 2017/01
Summary BACKGROUND:Many patients with schizophrenia have low medication adherence. There is, however, no objective assessment scale that can be used by nurses or caregiver specialists. The Nursing Assessment of Medication Acceptance (NAMA) was developed to assess patients' medication adherence. The aim of this study was to examine the validity and reliability of the NAMA in patients with schizophrenia.METHODS:A total of 121 Japanese patients with schizophrenia were enrolled. All patients underwent evaluation using the NAMA and the Drug Attitude Inventory (DAI-10). Reliability was investigated using a test-retest method and a parallel-test method. To determine the test-retest reliability of the NAMA, we tested 101 schizophrenia patients twice, with the second assessment 2-4 weeks after the date of the first assessment. For validity verification, standard-related validity and the degree of concordance with the DAI-10 scores were measured.RESULTS:The Cronbach's alpha value of the NAMA in schizophrenia was 0.88. The test-retest correlation coefficients were all between 0.53-0.74. The total scores and all subscores for the NAMA were significantly correlated, and the NAMA total scores were significantly correlated with the DAI-10 total scores.CONCLUSIONS:The NAMA shows good reliability and validity in measuring medication adherence in schizophrenia.
DOI 10.1177/2045125316672546
PMID 28101319